RxDoctor Payments DataLook up a doctor →

Gary Bedel, MD

Family Medicine · Franklin, OHNPI 1700803780

Payments from drug & device makers

$809,337in general payments, 2019–2025

Across 1,515 payments — averaging $534.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$316K
  • Novo Nordisk AS$311K
  • Kowa Research Institute, Inc.$106K
  • Esperion Therapeutics, Inc.$24K
  • Janssen Research & Development, LLC$21K
  • Ironwood Pharmaceuticals, Inc$12K
  • plus $21K from 33 others

What the payments were for

  • Travel & lodging$3,29221%
  • Food & beverage$12,46679%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$809,337 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$43,536
Medicare patients
141
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$128,574
EliquisApixaban34$46,583
Tresiba Flextouch U-200Insulin Degludec11$27,448
JardianceEmpagliflozin17$26,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,271
Breo ElliptaFluticasone/Vilanterol15$6,954
Rosuvastatin Calcium216$4,606
Esomeprazole Magnesium75$4,187
Celecoxib52$3,487
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,127
Atorvastatin Calcium359$3,052
Ezetimibe66$2,691
Albuterol Sulfate HfaAlbuterol Sulfate137$2,492
Levothyroxine Sodium151$1,937
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$1,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,423$128,57488 claims
PfizerEliquis$315,521$46,58334 claims
Boehringer IngelheimJardiance$3,209$26,28117 claims
GSKTrelegy Ellipta, Breo Ellipta$827$19,22526 claims
Sanofi-aventis U.S. LLCLantus$250$1,66811 claims
AbbVieSynthroid$571$1,16123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Franklin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →